The dose is not the same for everyone.
Midosis combines your personal context: body, sleep, food, hangover, experience, setting, and medications; with peer-reviewed dose-response research from MAPS, Johns Hopkins, Imperial College, and University Hospital Basel to suggest a conservative range for psilocybin, MDMA, or LSD.
One free guidance per email. We hash the address before storing, inputs are never sent to our servers beyond the dosage call. Results save on your device for 30 minutes by default; extend to 24 hours from the saved-results menu.
What this is
Most online resources give a static chart: 3.5 g of mushrooms is a heroic dose. But a 50 kg first-time user on 4 hours of sleep at a festival has a profoundly different risk profile from a 90 kg experienced user at home with a sitter. The same dose is two different experiences.
Midosis does what those charts don't: cross-reference your personal context with the dose-response curves established in clinical trials, screen for dangerous medication interactions, and produce a conservative range you can think about.
Personalized
Static dose charts ignore body weight, sleep, recent food, hangover, prior experience, and setting. We adjust the bands using deterministic formulas grounded in the published literature — never an LLM hallucination.
Peer-reviewed
Every dose band traces to a specific paper. Hasler 2004, Holze 2021, Studerus 2021, Garcia-Romeu 2021, and the MAPS Phase 3 protocols. Citations are visible on every result.
Anonymous
Your form data and results never touch our database. We persist only an HMAC-hashed email and a token balance. Refresh the page and your session is gone.
Sources
The dose tables and adjustment factors trace to these peer-reviewed papers. The LLM that writes the prose receives them as context but is never permitted to choose the numbers.
- Garcia-Romeu, Barrett, Carbonaro, Johnson, Griffiths (2021) — Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approachesJournal of Psychopharmacology
Pooled analysis of 10 Hopkins studies (2001–2018) finds body weight had no consistent effect on subjective response across 49–113 kg at 20–30 mg/70kg. Justifies a gentle (not strong) weight-adjustment factor.
- Hasler, Grimberg, Benz, Huber, Vollenweider (2004) — Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect studyPsychopharmacology
Classic 8 / 14 / 22 mg per 70 kg ladder. Foundation for our low/medium/high band cutoffs in pure psilocybin.
- Griffiths, Johnson, Richards, Richards, McCann, Jesse (2011) — Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effectsPsychopharmacology
Dose-effect on subjective intensity at 5 / 10 / 20 / 30 mg/70 kg; supports our medium/high band ranges.
- Spriggs, Giribaldi, Carhart-Harris et al. (2023) — Body mass index (BMI) does not predict responses to psilocybinJournal of Psychopharmacology
Imperial College finding that BMI does not predict subjective psilocybin response. Reinforces a conservative, gentle weight factor for psilocybin.
- Studerus, Vizeli, Harder, Ley, Liechti (2021) — Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studiesJournal of Psychopharmacology
Pooled n=194 from 10 placebo-controlled Basel studies. Identifies sex, drug pre-experience, social context, and genetics as predictors. Drives our experience and setting fields.
- Vizeli, Liechti (2017) — Safety pharmacology of acute MDMA administration in healthy subjectsJournal of Psychopharmacology
Cardiovascular safety bounds for 75–125 mg MDMA. Sets our high-band ceiling and informs cardiac contraindication.
- de la Torre, Farré, Ortuño et al. (2000) — Non-linear pharmacokinetics of MDMA ('ecstasy') in humansBritish Journal of Clinical Pharmacology
Doubling the dose more-than-doubles plasma levels. The reason 'redosing' or 'stacking' is dangerous and why we cap the high band at a single dose.
- Mitchell, Bogenschutz, Lilienstein, Harrison et al. (MAPS) (2021) — MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 studyNature Medicine
Establishes 80–120 mg + optional 40–60 mg booster as the supervised therapeutic range. We do NOT include boosters in v1; the medium-band ceiling reflects single-dose safety.
- Holze, Vizeli, Ley, Müller, Dolder, Stocker, Borgwardt, Liechti (2021) — Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjectsNeuropsychopharmacology
Definitive 25 / 50 / 100 / 200 µg ladder mapping subjective and autonomic effects. Anxiety appears at 100–200 µg. Our LSD bands map directly to this paper.
- Holze, Becker, Liechti et al. (2024) — Pharmacological and non-pharmacological predictors of the LSD experience in healthy participantsTranslational Psychiatry
Non-drug predictors (set, setting, prior experience, expectations) shape outcome. Justifies the form's setting and prior-experience fields.
- Hartogsohn (2017) — Constructing drug effects: A history of set and settingDrug Science, Policy and Law
Canonical synthesis of why context dominates psychedelic outcome. Source for the set/setting prose advice.
- Carhart-Harris, Roseman, Haijen, Erritzoe, Watts, Branchi, Kaelen (2018) — Psychedelics and the essential importance of contextJournal of Psychopharmacology
Empirical basis for the setting field's effect on the recommendation. Sets the framing for trusted-person / sitter / unfamiliar setting warnings.
This is not medical advice
Midosis aggregates peer-reviewed dose-response research and personal context to suggest a conservative range. It is informational only. The substances referenced are controlled and illegal in many jurisdictions. The tool cannot evaluate every drug interaction or individual risk. If you have any doubt, consult a qualified clinician, and start lower than you think you need.